OncoCyte Corporation
NASDAQ:OCX
2.84 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.881 | 1.503 | 0.958 | 7.727 | 1.216 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.141 | 1.09 | 0.976 | 7.539 | 1.855 | 0.344 | 0.559 | 0.58 | 0.387 | 0.283 | 0 | 0 |
| Gross Profit
| 0.74 | 0.413 | -0.018 | 0.188 | -0.639 | -0.344 | -0.559 | -0.58 | -0.387 | -0.283 | 0 | 0 |
| Gross Profit Ratio
| 0.393 | 0.275 | -0.019 | 0.024 | -0.525 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 9.839 | 9.294 | 7.301 | 13.631 | 9.8 | 6.794 | 6.514 | 7.174 | 5.677 | 4.527 | 3.962 | 2.943 |
| General & Administrative Expenses
| 10.204 | 10.741 | 21.881 | 22.336 | 16.788 | 13.281 | 7.007 | 9.232 | 5.463 | 4.191 | 1.011 | 0.552 |
| Selling & Marketing Expenses
| 3.944 | 2.795 | 1.132 | 11.167 | 6.494 | 2.164 | 1.681 | 2.443 | 1.198 | 0.324 | 0 | 0 |
| SG&A
| 14.148 | 13.536 | 23.013 | 33.503 | 23.282 | 15.445 | 8.688 | 11.675 | 5.463 | 4.191 | 1.011 | 0.552 |
| Other Expenses
| 38.157 | 2.719 | -0.067 | -0.037 | 0.027 | -0.003 | 0.091 | 0 | 0 | 0.002 | -0.011 | 0 |
| Operating Expenses
| 60.64 | 25.637 | 30.314 | 47.134 | 33.082 | 22.239 | 15.202 | 18.849 | 11.14 | 8.718 | 4.973 | 3.495 |
| Operating Income
| -61.041 | -25.136 | -17.997 | -46.946 | -29.711 | -22.239 | -15.202 | -18.849 | -11.14 | -8.718 | -4.973 | -3.495 |
| Operating Income Ratio
| -32.451 | -16.724 | -18.786 | -6.076 | -24.433 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.378 | 0.281 | -0.615 | 0.854 | -1.475 | -0.187 | -0.552 | -0.526 | -0.028 | -0.017 | -0.013 | 0 |
| Income Before Tax
| -60.663 | -24.855 | -18.612 | -73.358 | -31.186 | -22.426 | -15.754 | -19.375 | -11.168 | -8.735 | -4.986 | -3.495 |
| Income Before Tax Ratio
| -32.25 | -16.537 | -19.428 | -9.494 | -25.646 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 54.828 | -9.261 | -1.254 | -0.097 | -0.336 | 0.217 | -0.387 | -0.262 | -0.009 | 0 |
| Net Income
| -60.663 | -27.781 | -73.44 | -64.097 | -29.932 | -22.329 | -15.754 | -19.375 | -11.168 | -8.735 | -4.986 | -3.495 |
| Net Income Ratio
| -32.25 | -18.484 | -76.66 | -8.295 | -24.615 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -4.66 | -3.75 | -13.26 | -14.42 | -9.14 | -8.71 | -8.32 | -12.83 | -8.42 | -8.32 | -15.36 | -10.77 |
| EPS Diluted
| -4.66 | -3.75 | -13.26 | -14.42 | -9.14 | -8.71 | -8.32 | -12.83 | -8.42 | -8.32 | -15.36 | -10.77 |
| EBITDA
| -59.015 | -23.123 | -13.315 | -48.457 | -30.54 | -21.895 | -15.202 | -18.269 | -11.14 | -8.435 | -4.692 | -3.218 |
| EBITDA Ratio
| -31.374 | -15.385 | -13.899 | -6.271 | -25.115 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |